Integra LifeSciences Holdings Corporation (IART)
| Market Cap | 1.21B +4.8% |
| Revenue (ttm) | 1.65B +1.6% |
| Net Income | -7.24M |
| EPS | -0.10 |
| Shares Out | 77.77M |
| PE Ratio | n/a |
| Forward PE | 6.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 541,354 |
| Open | 15.06 |
| Previous Close | 15.22 |
| Day's Range | 14.91 - 15.55 |
| 52-Week Range | 8.70 - 20.49 |
| Beta | 1.21 |
| Analysts | Hold |
| Price Target | 19.56 (+25.87%) |
| Earnings Date | Oct 29, 2026 |
About IART
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after... [Read more]
Financial Performance
In 2025, IART's revenue was $1.64 billion, an increase of 1.53% compared to the previous year's $1.61 billion. Losses were -$516.47 million, 7337.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for IART stock is "Hold." The 12-month stock price target is $19.56, which is an increase of 25.87% from the latest price.
News
Integra LifeSciences Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Operational and quality improvements have restored product supply and compliance, enabling renewed commercial momentum. Growth is expected from new product launches, international expansion, and margin recovery, while capital allocation focuses on deleveraging and innovation. Watch for cash flow and sales force progress in the coming year.
Integra LifeSciences Holdings Transcript: Wells Fargo 21st Annual Healthcare Conference
Revenue and margin expansion are driven by improved supply reliability, operational discipline, and cost-saving initiatives. Growth is expected in international and specialty surgery markets, with new product launches and innovation fueling future performance. Free cash flow and refinancing plans support long-term objectives.
Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference
PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financ...
Integra LifeSciences Holdings Earnings Call Transcript: Q2 2026
Second quarter revenue and adjusted EPS exceeded expectations, driven by operational improvements and tariff favorability. Guidance for organic revenue growth and EPS was reaffirmed, with margin expansion and deleveraging as ongoing priorities. Product relaunches and supply chain improvements are expected to support future growth.
Integra LifeSciences Holdings Slides: Q2 2026
Integra LifeSciences Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Integra LifeSciences Holdings Earnings release: Q2 2026
Integra LifeSciences Holdings released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Integra LifeSciences Holdings Quarterly report: Q2 2026
Integra LifeSciences Holdings has published its Q2 2026 quarterly earnings report on July 29, 2026.
Integra LifeSciences Reports Second Quarter 2026 Financial Results
PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the secon...
Integra LifeSciences initiated with a Neutral at UBS
UBS initiated coverage of Integra LifeSciences (IART) with a Neutral rating and $19 price target The firm sees the company’s debt load as limiting the share upside. However, Integra faces…
Integra LifeSciences price target raised to $19 from $14 at Truist
Truist raised the firm’s price target on Integra LifeSciences (IART) to $19 from $14 and keeps a Hold rating on the shares as part of a broader research note previewing…
Integra LifeSciences to Host Second Quarter 2026 Financial Results Conference Call on July 29, 2026
PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2026 financial res...
BMO starts ‘show-me story’ Integra LifeSciences with a Market Perform
As previously reported, BMO Capital initiated coverage of Integra LifeSciences (IART) with a Market Perform rating and $19 price target While early signs of recovery – including a Q1 beat…
Integra LifeSciences initiated with a Market Perform at BMO Capital
BMO Capital analyst Vik Chopra initiated coverage of Integra LifeSciences (IART) with a Market Perform rating and $19 price target
Integra LifeSciences price target raised to $19 from $16 at Citi
Citi raised the firm’s price target on Integra LifeSciences (IART) to $19 from $16 and keeps a Neutral rating on the shares. For Q2 earnings season, given “the skittish trading…
Integra LifeSciences appoints Topaz Kirlew as chief regulatory officer
Integra LifeSciences (IART) announced the appointment of Topaz Kirlew as corporate vice president and chief regulatory officer. Kirlew will lead Integra’s global regulatory affairs organization and ov...
Integra LifeSciences Appoints Topaz Kirlew Chief Regulatory Officer
Kirlew will lead Integra's global regulatory affairs organization as the company continues to strengthen quality, compliance, and execution. Kirlew will lead Integra's global regulatory affairs organi...
Integra LifeSciences Announces Key Executive Appointments
PRINCETON, N.J., June 23, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Corporation Holdings (Nasdaq: IART), a global leader in medical technology, today announced several leadership appointments with...
Argus upgrades Integra LifeSciences to Buy after CEO’s return
As previously reported, Argus upgraded Integra LifeSciences (IART) to Buy from Hold with a $25 price target Shares have jumped 65% since the announcement on May 5 that Stuart Essig,…
Integra LifeSciences upgraded to Buy from Hold at Argus
Argus upgraded Integra LifeSciences (IART) to Buy from Hold with a $25 price target
Integra LifeSciences Holdings Transcript: Truist Securities MedTech Conference 2026
Leadership changes have renewed focus on customer engagement and portfolio strength, with key products like PriMatrix and SurgiMend returning to market. The business targets mid-single digit growth, is largely insulated from CMS changes, and expects 2027 growth to be driven by PMA approvals and product relaunches.
Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference
PRINCETON, N.J., June 15, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Bob Davis, executive vice...
Integra LifeSciences Holdings Transcript: Jefferies Global Healthcare Conference 2026
Management outlined ongoing operational transformation, product relaunches, and regulatory milestones, with a focus on execution and margin improvement. SurgiMend and DuraSorb PMA approvals are targeted for 2027, and capital allocation remains disciplined until financial targets are met.
Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference
PRINCETON, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief financial officer L...
Integra LifeSciences upgraded to Neutral from Sell at Citi
Citi analyst Joanne Wuensch upgraded Integra LifeSciences (IART) to Neutral from Sell with a price target of $16, up from $11. The company’s headwinds are easing with with improving supply…
Integra LifeSciences Holdings Transcript: Bank of America Global Healthcare Conference 2026
Leadership transition brings renewed focus on transformation and commercial growth, with operational improvements driving better Q1 results and lower volatility. Product relaunches and supply chain upgrades position the business for growth, while cost savings and debt reduction remain priorities.